STOCK TITAN

[Form 4] BioLife Solutions Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Sean Werner, Chief Technology Officer of BioLife Solutions, sold 111 shares of the company's common stock on 08/26/2025 at $25.44 per share under a pre-existing Rule 10b5-1(c) trading plan. The Form 4 shows the sale was to satisfy tax withholding obligations tied to the vesting of restricted stock and the reporting person retained 26,384 shares of common stock after the transaction. The filing is signed by Sean Werner on 08/28/2025 and indicates the Form is filed by one reporting person.

Sean Werner, Chief Technology Officer di BioLife Solutions, ha venduto 111 azioni del capitale sociale della società il 26/08/2025 a $25,44 per azione nell'ambito di un piano di negoziazione Rule 10b5-1(c) preesistente. Il Modulo 4 indica che la vendita è stata effettuata per soddisfare obblighi di ritenuta fiscale legati alla maturazione di azioni vincolate e che la persona soggetta a segnalazione ha mantenuto 26.384 azioni ordinarie dopo la transazione. La comunicazione è firmata da Sean Werner il 28/08/2025 e specifica che il Modulo è presentato da una sola persona obbligata alla segnalazione.

Sean Werner, Chief Technology Officer de BioLife Solutions, vendió 111 acciones del capital social de la empresa el 26/08/2025 a $25.44 por acción bajo un plan de negociación Rule 10b5-1(c) preexistente. El Formulario 4 muestra que la venta se realizó para satisfacer obligaciones de retención fiscal vinculadas a la consolidación de acciones restringidas y que la persona informante retuvo 26.384 acciones ordinarias tras la operación. La presentación está firmada por Sean Werner el 28/08/2025 e indica que el formulario lo presenta una sola persona informante.

BioLife Solutions의 최고기술책임자(Chief Technology Officer) Sean Werner는 2025년 8월 26일 기존의 Rule 10b5-1(c) 거래계획에 따라 보통주 111주를 주당 $25.44에 매도했습니다. Form 4에는 해당 매각이 제한주(리스트릭티드 스톡)의 가속 취득(vesting)에 따른 세금 원천징수 의무를 충족하기 위한 것임이 기재되어 있으며, 보고인은 거래 후 보통주 26,384주를 보유하고 있었습니다. 서류는 Sean Werner가 2025년 8월 28일 서명했으며, 해당 양식이 한 명의 보고인에 의해 제출되었음을 나타냅니다.

Sean Werner, Chief Technology Officer de BioLife Solutions, a vendu 111 actions ordinaires de la société le 26/08/2025 au prix de 25,44 $ par action dans le cadre d'un plan de négociation Rule 10b5-1(c) préexistant. Le formulaire 4 indique que la vente a été réalisée pour satisfaire des obligations de retenue fiscale liées à l'acquisition des actions restreintes et que la personne déclarée détenait 26 384 actions ordinaires après la transaction. Le dépôt est signé par Sean Werner le 28/08/2025 et précise que le formulaire est déposé par une seule personne déclarante.

Sean Werner, Chief Technology Officer von BioLife Solutions, verkaufte am 26.08.2025 111 Aktien des Stammkapitals des Unternehmens zu je $25,44 im Rahmen eines bestehenden Rule-10b5-1(c)-Handelsplans. Das Formblatt 4 weist aus, dass der Verkauf zur Erfüllung von Steuerabzugsverpflichtungen im Zusammenhang mit der Vesting von Restricted Stock erfolgte und die meldende Person nach der Transaktion 26.384 Stammaktien behielt. Die Einreichung ist von Sean Werner am 28.08.2025 unterzeichnet und gibt an, dass das Formular von einer einzelnen meldenden Person eingereicht wurde.

Positive
  • Transaction executed under Rule 10b5-1 plan, indicating pre-established trading instructions and reduced insider timing concerns
  • Full disclosure of post-transaction ownership: reporting person retains 26,384 shares
Negative
  • None.

Insights

TL;DR: A routine insider sale under a 10b5-1 plan to cover tax withholding; no new governance issues disclosed.

The Form 4 documents a small, clearly disclosed sale of 111 shares at $25.44 executed under a Rule 10b5-1(c) plan adopted 02/24/2022. Because the sale was tied to tax withholding for restricted stock vesting and executed under a pre-established plan, this is consistent with ordinary insider liquidity and compensation settlement practices. The disclosure includes post-transaction beneficial ownership of 26,384 shares, providing transparency about the reporting person’s ongoing stake. There are no indications of unusual timing or additional derivative activity in this filing.

TL;DR: Transaction is immaterial to company valuation but is a confirmatory disclosure of insider compensation settlement.

The sale of 111 shares is quantitatively minor relative to the reported holding and was executed at a single price of $25.44. The filing explicitly states the sale was made pursuant to a 10b5-1 plan to satisfy tax withholding for vested restricted shares, which explains the rationale and timing without implying trading on nonpublic information. No derivative securities transactions or amendments are reported. The signature date of 08/28/2025 completes the Form 4 disclosure requirements.

Sean Werner, Chief Technology Officer di BioLife Solutions, ha venduto 111 azioni del capitale sociale della società il 26/08/2025 a $25,44 per azione nell'ambito di un piano di negoziazione Rule 10b5-1(c) preesistente. Il Modulo 4 indica che la vendita è stata effettuata per soddisfare obblighi di ritenuta fiscale legati alla maturazione di azioni vincolate e che la persona soggetta a segnalazione ha mantenuto 26.384 azioni ordinarie dopo la transazione. La comunicazione è firmata da Sean Werner il 28/08/2025 e specifica che il Modulo è presentato da una sola persona obbligata alla segnalazione.

Sean Werner, Chief Technology Officer de BioLife Solutions, vendió 111 acciones del capital social de la empresa el 26/08/2025 a $25.44 por acción bajo un plan de negociación Rule 10b5-1(c) preexistente. El Formulario 4 muestra que la venta se realizó para satisfacer obligaciones de retención fiscal vinculadas a la consolidación de acciones restringidas y que la persona informante retuvo 26.384 acciones ordinarias tras la operación. La presentación está firmada por Sean Werner el 28/08/2025 e indica que el formulario lo presenta una sola persona informante.

BioLife Solutions의 최고기술책임자(Chief Technology Officer) Sean Werner는 2025년 8월 26일 기존의 Rule 10b5-1(c) 거래계획에 따라 보통주 111주를 주당 $25.44에 매도했습니다. Form 4에는 해당 매각이 제한주(리스트릭티드 스톡)의 가속 취득(vesting)에 따른 세금 원천징수 의무를 충족하기 위한 것임이 기재되어 있으며, 보고인은 거래 후 보통주 26,384주를 보유하고 있었습니다. 서류는 Sean Werner가 2025년 8월 28일 서명했으며, 해당 양식이 한 명의 보고인에 의해 제출되었음을 나타냅니다.

Sean Werner, Chief Technology Officer de BioLife Solutions, a vendu 111 actions ordinaires de la société le 26/08/2025 au prix de 25,44 $ par action dans le cadre d'un plan de négociation Rule 10b5-1(c) préexistant. Le formulaire 4 indique que la vente a été réalisée pour satisfaire des obligations de retenue fiscale liées à l'acquisition des actions restreintes et que la personne déclarée détenait 26 384 actions ordinaires après la transaction. Le dépôt est signé par Sean Werner le 28/08/2025 et précise que le formulaire est déposé par une seule personne déclarante.

Sean Werner, Chief Technology Officer von BioLife Solutions, verkaufte am 26.08.2025 111 Aktien des Stammkapitals des Unternehmens zu je $25,44 im Rahmen eines bestehenden Rule-10b5-1(c)-Handelsplans. Das Formblatt 4 weist aus, dass der Verkauf zur Erfüllung von Steuerabzugsverpflichtungen im Zusammenhang mit der Vesting von Restricted Stock erfolgte und die meldende Person nach der Transaktion 26.384 Stammaktien behielt. Die Einreichung ist von Sean Werner am 28.08.2025 unterzeichnet und gibt an, dass das Formular von einer einzelnen meldenden Person eingereicht wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Werner Sean

(Last) (First) (Middle)
3303 MONTE VILLA PARKWAY
SUITE 310

(Street)
BOTHELL WA 98021

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technology Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/26/2025 S(1) 111 D $25.44 26,384 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Remarks:
/s/ Sean Werner 08/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BLFS CTO Sean Werner report on Form 4?

The Form 4 reports a sale of 111 shares of BioLife Solutions common stock on 08/26/2025 at a price of $25.44 per share.

Why were the 111 shares sold according to the Form 4 for BLFS?

The sale was made pursuant to a Rule 10b5-1(c) trading plan adopted 02/24/2022 to satisfy tax withholding obligations related to the vesting of restricted stock.

How many BLFS shares does Sean Werner own after the reported transaction?

The Form 4 shows 26,384 shares beneficially owned following the reported sale.

Was the Form 4 filed jointly or by a single reporting person?

The filing was made by one reporting person, Sean Werner, and is signed on 08/28/2025.

Does the Form 4 disclose any derivative security transactions for BLFS by the reporting person?

No. Table II for derivative securities contains no reported transactions in this filing.
Biolife Solutions Inc

NASDAQ:BLFS

BLFS Rankings

BLFS Latest News

BLFS Latest SEC Filings

BLFS Stock Data

1.20B
46.85M
2.13%
104.31%
8.26%
Medical Instruments & Supplies
Electromedical & Electrotherapeutic Apparatus
Link
United States
BOTHELL